Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2021-03-10 Regulatory Filings
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1922 characters) and its primary content is an announcement regarding a 'Price Monitoring Extension' for a security on the London Stock Exchange, referencing an 'RNS Number'. It explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief notification about a market event or administrative update provided via the RNS system—fits best under the general Regulatory Filings category, as it is not a specific financial report (like 10-K, IR, ER) nor a specific corporate action announcement (like DIV, SHA, DIRS). It is a general regulatory/market notice.
2021-03-10 English
AGY to Present at H.C. Wainwright Conference
Regulatory Filings Classification · 99% confidence The document is very short (3727 characters) and its primary purpose is to announce that company executives will be presenting at an external conference (H.C. Wainwright Global Life Sciences Conference) and that a replay will be made available online. It does not contain detailed financial statements, management discussion, or formal regulatory disclosures like a 10-K or IR. The presence of the 'RNS Number' and the closing statement referencing RNS (the news service of the London Stock Exchange) indicates it is a general regulatory announcement. Since it is an announcement about an event/presentation rather than a specific report type (like ER, IP, or MDA), and it fits the criteria of a short announcement about company activity distributed via a regulatory feed, the most appropriate classification is Regulatory Filings (RNS) as a general announcement.
2021-03-08 English
Interim Results for six months ended 31 Dec 2020
Earnings Release Classification · 99% confidence The document explicitly states it contains 'Interim Results for the six months ended 31 December 2020'. It provides detailed financial highlights (Revenue, Profit, Cash balance) and operational updates for a period shorter than a year (six months). This structure and content perfectly match the definition of an Interim/Quarterly Report. The RNS Number suggests it was filed via a regulatory news service, but the core content is the comprehensive interim financial report itself, not just an announcement of its publication. Therefore, the classification is 'Interim / Quarterly Report' (IR). H1 2021
2021-03-03 English
Group of companies' accounts made up to 2020-06-30
Regulatory Filings
2021-02-09 English
Block Listing Return and Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is identified by the 'RNS Number' header and explicitly states it is being provided by 'RNS, the news service of the London Stock Exchange.' The content details a 'Block Listing Return' regarding the issuance of shares under an incentive plan and provides an update on the 'Total Voting Rights' as of January 15, 2021, referencing FCA Disclosure Guidance and Transparency Rules (DTR 5.6.1). This type of mandatory, periodic disclosure regarding share capital structure and voting rights, distributed via the official regulatory news service (RNS), fits best under the general 'Regulatory Filings' category, as there is no specific code for 'Block Listing Return' or 'Total Voting Rights Update' among the provided options, and it is not a full financial report (10-K, IR) or an earnings release (ER).
2021-01-15 English
Half Year Trading Update 2021 & Notice of Results
Regulatory Filings Classification · 98% confidence The document is titled 'Half Year Trading Update 2021 and Notice of Results' and provides key financial highlights (revenues, cash balance) for the six months ended 31 December 2020. It explicitly states that the full Half Year Results will be announced on 3 March 2021. This structure—providing preliminary performance data for an interim period ahead of the full report release—is characteristic of an Earnings Release (ER). Although it contains some operational updates, the primary focus is the financial trading update for the interim period. It is not the comprehensive Interim Report (IR) itself, but the initial announcement of the results, fitting the definition of an Earnings Release (ER). The presence of the RNS Number and the 'ENDS' marker confirms it is a regulatory announcement.
2021-01-13 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.